How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.comA Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer
Description:
IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Sponsor:
Unknown Organization
Phase:
Early Phase 1
Contacts:
Immunome Medical Monitor (CONTACT)info@immunome.com
425.939.7410
Government Study Link:
NCT07505771 - Click here to see study onClinicalTrials.gov
IM-3050
Isotope(s):
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
Target(s):
- FAP
Ligand Class: Small Molecules
Chelator: DOTA
Inclusion
- Histological or cytological diagnosis of a solid tumor
- During screening, participants must have positive FAP PET/CT uptake as described in criteria for continuation of IM-3050 treatment.
Exclusion
Exclusion Criteria Not Yet Provided
Share your feedback
Help us improve your experience